» Articles » PMID: 9457289

Rapid Exponential Elimination of Free Prostate-specific Antigen Contrasts the Slow, Capacity-limited Elimination of PSA Complexed to Alpha 1-antichymotrypsin from Serum

Overview
Journal Urology
Specialty Urology
Date 1998 Feb 11
PMID 9457289
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To study the rates of elimination of total prostate-specific antigen (PSA-T), free PSA (PSA-F), and PSA complexed to alpha 1-antichymotrypsin (PSA-ACT) from blood after radical retropubic prostatectomy (RRP).

Methods: We obtained venous blood from 10 patients with prostate cancer who were undergoing RRP. We analyzed PSA-F and PSA-ACT and equimolar detection of both of these forms together (PSA-T) by using immunofluorometric assays. An attempt was made to fit the serum concentrations of PSA-F, PSA-ACT, and PSA-T for each patient to exponential curves by applying one- and two-compartment models for pharmacokinetic analysis.

Results: Manipulation of the prostate during RRP resulted in a 3- to 28-fold increase in PSA-F concentrations in serum. Removal of the prostate resulted in a rapid, biexponential elimination of PSA-F from serum, corresponding to a mean initial (alpha) half-life of 0.81 hours and a mean terminal (beta) half-life of 13.9 hours. Serum PSA-ACT concentrations decreased by 20% to 40% immediately after removal of the gland; the elimination after surgery was slow and nonexponential, corresponding to a mean rate of 0.8 ng/mL/day. The elimination of PSA-T reflects a combination of the elimination patterns for PSA-F and PSA-ACT.

Conclusions: The main proportion of PSA-F is rapidly eliminated from serum, possibly by glomerular filtration. PSA-F released during surgery did not form complexes with ACT, as suggested by the lack of PSA-ACT elevation in serum. The size (approximately 90 kDa) and the extensive in vitro stability of the PSA-ACT complex prevents renal clearance. The nonexponential elimination of the PSA-ACT complex is evidence of a capacity-limited process (e.g., metabolic transformation).

Citing Articles

A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer.

Srinivasan S, Kryza T, Bock N, Tse B, Sokolowski K, Janaththani P Nat Commun. 2024; 15(1):9587.

PMID: 39505858 PMC: 11541583. DOI: 10.1038/s41467-024-52472-6.


Predictive value of kallikrein forms and β-microseminoprotein in blood from patients with evidence of detectable levels of PSA after radical prostatectomy.

Pellegrino F, Sjoberg D, Tin A, Benfante N, Briganti A, Montorsi F World J Urol. 2023; 41(6):1489-1495.

PMID: 37209144 PMC: 10547122. DOI: 10.1007/s00345-023-04420-0.


The Role and Significance of Bioumoral Markers in Prostate Cancer.

Constantin T, Savu D, Bucur S, Predoiu G, Constantin M, Jinga V Cancers (Basel). 2021; 13(23).

PMID: 34885045 PMC: 8656561. DOI: 10.3390/cancers13235932.


PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones.

Kostova M, Brennen W, Lopez D, Anthony L, Wang H, Platz E Prostate. 2018; 78(11):819-829.

PMID: 29659051 PMC: 8147660. DOI: 10.1002/pros.23539.


The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer.

Maccini M, Westfall N, Van Bokhoven A, Lucia M, Poage W, Maroni P Prostate. 2018; 78(7):506-511.

PMID: 29460452 PMC: 6237549. DOI: 10.1002/pros.23495.